Oxford BioMedica not threatened by Bavarian Nordic's renewed patent claims
This article was originally published in Scrip
Executive Summary
Oxford BioMedica's CEO John Dawson has branded Bavarian Nordic's renewed efforts to bring a patent infringement suit against the UK-based company as baseless and "an improper attempt to impede [its] continuing endeavours to pursue legitimate collaborative development of TroVax for the potential benefit of cancer patients".